Sanofi Loses Last-Ditch Bid To Upend Eloxatin Deal

By Erin Fuchs

Law360, New York (March 02, 2010, 6:47 PM ET) -- A federal judge has deemed enforceable a deal that Sanofi-Aventis U.S. LLC reached with Sun Pharmaceutical Industries Ltd. ending a patent fight over generic versions of Sanofi's colon cancer drug Eloxatin, rejecting Sanofi's second attempt to undo the deal.

U.S. Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Monday denied Sanofi's motion for an order declaring the settlement between the companies unenforceable.

The judge ruled in October that a binding agreement between the companies had in fact been reached,...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles